Core Viewpoint - SciSparc Ltd. has announced an advancement in its collaboration with NeuroThera Labs Inc. for a novel combination therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD) [1] Group 1: Company Overview - SciSparc Ltd. holds a controlling interest of approximately 75% in NeuroThera Labs Inc., which focuses on developing treatments for central nervous system disorders [1] - SciSparc is engaged in clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [4] Group 2: Collaboration and Patent Development - NeuroThera Labs has published an international patent application for a combination therapy involving 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) [2] - The combination therapy aims to address obesity and MASLD, which affects over 890 million adults and approximately 30% of the global adult population, respectively [2] Group 3: Market Potential - The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease [3] - The MEAI-PEA combination is expected to provide a safer and more cost-effective alternative to GLP-1 agonists for treating obesity and MASLD [2][3]

Group 1 - Novo Nordisk announced the acquisition of Akero Therapeutics for up to $5.2 billion in cash, indicating a strategic move into the fatty liver disease treatment market [1] - This acquisition reflects Novo Nordisk's commitment to expanding its portfolio in the area of metabolic diseases, particularly focusing on non-alcoholic fatty liver disease (NAFLD) [1] - The deal is part of Novo Nordisk's broader strategy to enhance its offerings in chronic disease management, aligning with the growing demand for effective treatments in this therapeutic area [1]